CompletedPhase 4

The Gut Microbiome in Women With Polycystic Ovary Syndrome

Novel Strategies in Weight Loss in Women With Polycystic Ovary Syndrome: do Changes in the Gut Microbiome Play a Role?

Lead sponsor

Universitaire Ziekenhuizen KU Leuven

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

Actual enrollment

Study population

Obesity / overweight, PCOS

Eligibility highlights

•BMI ≥27•Female

Primary endpoint

•Weight loss

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT03642600

Org study IDS61338

Timeline

Milestones

Study first posted2018-08-22actual

Study start2019-02-28actual

Primary completion2020-02-01actual

Study completion2020-07-03actual

Last update posted2020-11-04actual

Assets

Investigational agents

Liraglutide

Who this study enrolls

Obesity / overweightPCOS

Who can enroll

Minimum age18 Years

Maximum age40 Years

SexFemale

Healthy volunteersNot accepted

Inclusion criteria

•PCOS according to ROtterdam criteria

•BMI ≥ 27 kg/m2 and at risk of metabolic syndrome or BMI ≥ 30 kg/m2

Exclusion criteria

•pregnancy

•pancreatitis (in the past)

•oral contraceptive pill use

•inflammatory bowel disease

•auto-immune disease

•immuno-modulatory drugs

•antidiabetic drugs

•anti-inflammatory drugs

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

1 endpoint

Primary/protocol endpoint/low confidence

weight loss

Time frame:32 weeks

descriptive, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 6, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.